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Abstract
Obesity is defined as a BMI greater than 25 kg/m2. Once thought to simply be a 
nutritional disorder, obesity has become a major health concern characterized by a 
state of constant low-grade inflammation caused by chronic adiposity. This state of 
inflammation is characterized by circulating inflammatory mediators, such as IL-6, 
leptin, and TNF-α, as well as varying levels of glucose-regulating hormones pro-
duced by obese adipose tissue. When left untreated, obesity can lead to a number of 
diseases including, but not limited to, cardiovascular disease, metabolic syndrome, 
neurodegeneration, type II diabetes mellitus, chronic kidney disease, and infertil-
ity. The distribution of adiposity differs in men and women, and these differences, 
along with the differences in sex hormones and sex hormone levels, can exacerbate 
or attenuate the course of disease pathology. Obesity can also be exacerbated by 
stress, which can worsen disease pathogenesis. In this review, we will explore how 
obesity affects inflammation and disease and how sex can affect the course of these 
diseases.
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1. Introduction
Approximately 70% of the US adult population is considered overweight or 
obese [1]. Obesity has been associated with an elevated risk of type II diabetes, 
cancer, neurodegeneration, infertility and stress hypertension, and cardiovascular 
disease (CVD)[2, 3]. The increased risk for various health risks is due in part to the 
inflammatory adipokines produced by the adipose tissue itself. Clinically, body 
mass index (BMI) is the most widely used tool to measure adiposity. However, 
BMI measures total mass, including both fat and fat-free (lean) mass, so it is a 
poor indicator of adiposity [2]. Further, the different compartments of fat and 
different types of adipose tissue within these compartments play a major role in 
the overall increased health risks associated with increases in adiposity [4]. Lastly, 
the body composition differs between men and women; men have more lean mass 
than women, whereas women have more fat mass. In this book chapter, we help to 
unravel the differences in adipose-induced inflammation in men and women and 
how these differences may contribute to various pathophysiologies.
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2. Adipose tissue
Adipose tissue is composed of a variety of cells, including adipocytes, macro-
phages, leukocytes, endothelial cells, and fibroblasts. This metabolic tissue and 
the subsets of cells found within this tissue play a role in both the inflammatory 
and hormonal pathways. This has led many to believe that adipose tissue is a novel 
endocrine organ [5].
Classically adipocytes were believed to be either white or brown adipocytes. 
The white adipose tissue (WAT) is the adipose tissue which is often focused on 
in obesity research. The WAT is less metabolically active, is composed primarily 
of stored triglycerides, and produces adipokines which regulate hunger, satiation 
via leptin, breakdown of triglycerides via adiponectin, and insulin sensitivity via 
IL-1 and IL-6 [5]. WAT has also been associated with inflammatory adipokine 
production, including TNF-alpha, MCP-1, resistin, and IL-6 [5]. Interestingly, 
these adipokines become dysregulated in obese states which can further exacer-
bate cellular and systemic dysfunctions [6]. The increase in inflammatory cyto-
kines is a contributing factor to the various pathophysiologies discussed within 
this chapter.
Brown adipose tissue (BAT) is colored brown due to the high mitochondrial 
content. This highly metabolically active tissue also plays a role in thermogenesis, 
classically in neonates, and in lipid breakdown [7]. Key features of BAT include 
the high levels of mitochondria and the presence of uncoupling protein 1 (UCP-
1), which both play a role in the “extraction” of nutrients from free fatty acids 
and triglycerides [8, 9]. Recent studies have shown that BAT is not only found in 
neonates but can also be found in adults. A study conducted in males and females 
using PET-CT scans detected BAT tissue in the fascial plane in the ventral trunk and 
superficial and lateral sternocleidomastoid muscles [10]. Further, this study showed 
that there were differences in BAT mass in males and females, with females having 
more BAT than males. There was also an inverse correlation in BAT detection with 
age and BMI in older patients [10]. The data of this study suggest that shifting WAT 
to BAT also known as “beiging WAT” or increasing BAT production may be an effec-
tive treatment against obesity [11].
3. Sex differences in hormones and adipose tissue
The sex hormones, most notably testosterone (androgen) in males and estrogen 
and progesterone in females, play a role in fat deposition, metabolism, and energy 
balance within their respective sex. We will briefly discuss the specific roles of the 
sex hormones as they relate to adipose tissue. Estrogen has been shown to have both 
anti-inflammatory and antioxidant properties and can regulate metabolism [12]. 
Much of the data supporting estrogen as a protective factor comes from differences 
observed between pre- and postmenopausal women, where women in the pre-
menopausal phase are protected against many cardiometabolic diseases, until they 
reach the menopausal period, where there is an increase in CVDs, inflammation, 
and weight gain [13]. Low testosterone levels in men have also been associated as 
a risk factor for pathophysiologies, including sexual dysfunction, CVD, insulin 
sensitivity, and type II diabetes [14].
Conversely, high levels of estrogen in men and high levels of testosterone in 
women have been shown to have negative effects on weight gain [15]. High levels of 
testosterone, seen in women with polycystic ovarian syndrome (PCOS), or low lev-
els of estrogen seen in postmenopausal women have been linked to increased weight 
gain, specifically in the intra-abdominal fat [16]. Further, in men, testosterone 
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replacement, when there are low levels of testosterone, has been shown to increase 
lean body mass and improve lipid and cholesterol levels [17, 18].
More recent studies have shown that while both estrogen and androgens are 
important for many physiological processes, the estrogen to androgen ratio is 
important in regulating adipose tissue deposition. Interestingly in a study looking 
at the effects of testosterone replacement therapy, men with the lowest levels of 
estrogen (<10 pg./mL) had the largest decrease in body fat reduction after 6 months 
of testosterone therapy [19]. An important step in the production of estrogen is the 
enzyme aromatase, which converts testosterone to estrogen. Both male and female 
aromatase null mice exhibited increased weight gain and obesity-related metabolic 
complications [20]. Together, these data suggest that both estrogen and testosterone 
play an important role in regulating obesity and adiposity.
As stated previously, the body composition differs between men and women. 
Men are more likely to accumulate adipose tissue around the trunk and abdomen, 
whereas women usually accumulate adipose tissue around the hips and thighs  
[21, 22]. Women have a higher percentage of body fat than lean fat when compared 
to men who have the same BMI. Therefore, the health consequences are different 
for each gender at the same BMI [21]. In addition, a higher portion of that fat is 
in the femoral-gluteal region as compared to the abdominal region for men [22]. 
Studies have shown that the relative distribution of fat has a greater impact on 
CVD risks than total excess body fat. The female pattern of fat distribution, around 
the femoral-gluteal area, is relatively protective, compared to the male pattern of 
abdominal fat accumulation [23–25].
Within the abdomen, fat can accumulate in the subcutaneous area, subcutaneous 
adipose tissue (SAT), or, in the deep abdomen, visceral adipose tissue (VAT). Both 
VAT and SAT, in the obese state, produce increased inflammatory cytokines, includ-
ing TNF-α and IL-6, which produce increased levels of leptin and decreased levels 
of adiponectin [26, 27]. These changes can cause further inflammatory cascades, 
including inducing proinflammatory macrophages into the adipose tissue (Figure 1). 
Figure 1. 
The effects of lean vs. obese adipose tissue. A healthy diet and exercise are characterized by lean adipose 
tissue. Lean adipose tissue aids in regulating inflammation by secreting anti-inflammatory cytokines as well 
as secreting high levels of adiponectin which aids in insulin sensitivity [27]. Leaner adipose tissue also secretes 
low levels of leptin and resistin. Conversely, obese adipose tissue release high levels of resistin and leptin 
which promote insulin insensitivity. Obese adipose tissue also exhibits a proinflammatory cytokine profile 
which can lead to diseases such as diabetes and neurodegeneration. Men tend to have a greater ratio of lean 
to obese adipose tissue since they have greater muscle mass compared to women who have more obese adipose 
tissue [28].
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These inflammatory cells exacerbate adipose tissue cytokine production or increase 
disease risks, which can further feed into this cycle.
Multiple studies have also shown that VAT is associated with a higher cardiovas-
cular risk [24, 25]. Since the VAT has primarily been associated with the abdominal 
region, the VAT has historically played a more pathogenic role in male pathology. 
Because of the high rate of obesity in the United States, and the increased VAT 
deposition seen in both men and women, we understand that VAT deposition also 
increases risks in females. Therefore, more therapeutic interventions are needed to 
inhibit VAT deposition in both men and women.
4. Gender-specific differences in aging due to inflammation
Considerable amounts of data indicate that sex-specific differences in both 
acute and chronic inflammatory responses exist between males and females across 
multiple species and that these differences are altered with advancing age. Various 
studies suggest that these sex-specific variances include differences in multiple 
inflammatory biomarkers, including TNF-alpha, IL-6, IL-10, and C-reactive 
protein (CRP)[29]. While it appears clear that variations between the sexes do exist 
and these variations change with aging, the exact fluctuations in inflammatory 
biomarkers, both between sexes and with aging, are not fully elucidated.
Complicating matters is the established role of adipose tissue as a source of both 
pro- and anti-inflammatory cytokines. Leptin, adiponectin, and other cytokines 
synthesized and secreted by adipose tissue have been shown to play a profound role 
in modulating both systemic and localized inflammatory reactions. Adipose tissue 
likely plays a role as a source of pro- and anti-inflammatory cytokines and since, 
as previously described, males and  females accumulate adipose tissue in different/ 
store body fat in different locations, the adipose tissue plays an important role in the 
sex-specific differences in inflammatory responses, especially with aging.
Another complicating factor regarding inflammatory responses between males 
and females is the potential role of steroid hormones in various sex-specific physi-
ological responses, including accumulation and storage of adipose tissue, and 
inflammation. Estrogen has been shown to have potent anti-inflammatory activity 
and cardioprotective effects in females, and as estrogen levels decline with age after 
the onset of menopause, these protective effects of estrogen are minimized [12, 30]. 
While much has been determined, further study into the sex-specific differences 
between males and females, how these levels change over time with aging in a sex-
specific manner, and the role that these levels and their changes play in both acute 
and chronic diseases are warranted.
Many biomarkers of inflammation have been investigated regarding adiposity, 
age, sex, and ethnic variations. The most studied biomarkers include C-reactive 
protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor 
alpha (TNF-alpha). Data from a meta-analysis investigating potential relationships 
between the adipose tissue-derived cytokines leptin and adiponectin and inflam-
matory biomarkers including CRP, IL-6, and TNF-alpha suggested a positive 
correlation between leptin and all three inflammatory biomarkers, whereas there 
was a negative correlation with respect to adiponectin and the biomarkers [31]. 
When adjusted for age, Grassman et al. observed that correlations weakened as the 
age of the participants increased. In contrast to other studies, the authors found no 
significant differences when looking at sex and inflammatory markers in relation 
to adipose tissue. In another study aimed at elucidating mechanisms responsible 
for differences in inflammatory responses across sexes, Wegner et al. found that 
proinflammatory responses to endotoxin in women were greater compared to 
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men, with significantly higher increases in plasma TNF-alpha and IL-6 [32]. 
Interestingly, increases in circulating plasma cortisol levels were also found to be 
significantly elevated in women as compared to men, which could play a role in the 
heightened response.
In contrast Kuo et al. used endotoxin exposure in young (5–6 weeks) versus 
adult (9–10 weeks) male and female mice to investigate relationships in the inflam-
matory responses in these groups [33]. Older male mice showed significantly 
higher levels of pro-inflammatory markers IL-6, IL-10, and TNF-alpha than age-
matched female mice upon stimulation with endotoxin. In younger mice, however, 
they did not find a gender-specific difference in these same biomarkers. An investi-
gation of factors associated with biomarkers of systemic inflammation using age-, 
sex-, and body mass index (BMI)-adjusted linear regression found an age-related 
effect on the markers. They examined multiple factors in relation to inflammatory 
biomarkers including CRP, IL1β, IL6, IL8, and TNFα in adults between the ages of 
50 and 76 years. The results of this study indicated that age influenced circulating 
concentrations of all biomarkers except IL1β, with increasing age being associated 
with higher concentrations of all other biomarkers tested [34]. When they looked 
at sex-specific differences, the results were varied, with CRP and IL-6 levels being 
lower among men.
In looking at sex-specific differences of oxidative stress and inflammation 
with regard to cardiovascular risk factors in Arab populations, Khadir et al. found 
that females had higher levels of reactive oxygen species (ROS) and CRP after 
adjustment for body mass index (BMI) and waist circumference [35]. Conversely, 
males had increased levels of IL-6, IL-8, and TNF-alpha. In order to look at the 
relative impact of central obesity versus general obesity, the authors adjusted for 
age, BMI, and gender and noted that the levels of IL-6, TNF-alpha, and ROS were 
associated with central obesity but not general obesity, further suggesting that 
sex-specific patterns of adipose distribution can potentially account for some of 
the observed sex-specific differences in males versus females. The authors con-
cluded that the relative contribution of inflammation and oxidative stress to CVD 
in Arab populations was linked, at least in part, to gender-specific distributions of 
body fat [35].
5. Sex differences in obesity-induced inflammation in pathology
While it is well known that obesity is a risk factor for many diseases, it is impor-
tant to understand that the chronic state of inflammation associated with obesity 
further exacerbates obesity itself. Therefore, in many cases, obesity and inflamma-
tion increase pathophysiology, and these pathophysiologies further exacerbate the 
inflammation and obesity in a continuous vicious cycle. It is important to under-
stand the role of sex and the sex hormones in this vicious cycle in order for better/
more effective treatments and treatment plans for obese patients with various 
pathophysiologies. Below we describe the role of the sex hormones on obesity-
induced inflammation in metabolic syndrome, CVD, type II diabetes, chronic 
kidney disease (CKD), neurodegeneration, cancer, infertility, and stress.
5.1 Metabolic syndrome
Metabolic syndrome (MetS), also known as syndrome x, is a health condition 
characterized by insulin resistance, glucose intolerance, hypertension, high triglyc-
erides, low HDL cholesterol, abdominal obesity, dyslipidemia, and inflammation 
[36]. The increased incidence of MetS has been linked to obesity and a lack of 
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physical activity [37]. According to the Centers for Disease Control (CDC), a review 
of the NHANES data shows that as of 2012 more than one-third of US adults were 
considered to have MetS [38]. MetS affects over 30% of people by the time they 
reach age 65, and these statistics are expected to rise in the upcoming years [26]. By 
simply losing 5–10% of body weight, risk of developing metabolic syndrome, CVD, 
and type 2 diabetes is reduced significantly [26]. This emphasizes that prevention, 
rather than treatment, is the key to reducing the prevalence of metabolic syndrome 
in those at risk and those who are pre-symptomatic.
Diagnostic criteria for metabolic syndrome vary among organizations but typi-
cally include blood pressure, a large waist circumference, and the following: high 
levels of triglycerides and blood glucose and low levels of high-density lipoprotein 
cholesterol [26, 37, 39]. Previous diagnoses relied on body mass index; however, this 
has recently shifted to favor waist circumference because of its role in identifying 
central/abdominal obesity [36]. As previously described in this chapter, abdominal/
central obesity, with increased VAT, has been associated with increased risks for 
disease and inflammation.
Interestingly, there is no difference in prevalence of MetS between men and 
women, but there are differences in symptoms among men and women; women are 
more likely to have abdominal obesity, whereas men have more varied symptoms 
[36]. As previously described, intra-abdominal obesity is not classically associ-
ated with women and, therefore, may play a more pronounced role in this gender. 
Further, it has been shown that women throughout their lives have consistently 
higher levels of adiponectin which increases insulin sensitivity and leptin, which 
signals fullness to the brain than males. This implies that the adipose tissue in 
women produces adipokines which play a role in female adipose deposition and 
regulation [40–43].
It is well known that brown adipose tissue (BAT) is characterized by the expres-
sion of UCP-1 which causes an increase in mitochondrial function and metabolism 
[44, 45]. UCP-1 has been linked to the “beiging of WAT” and a more metabolically 
active tissue. Further, in oxidative phosphorylation, genes, responsible for assisting 
in transcriptional activation in the mitochondria, have increased levels of expres-
sion in women [41]. The upregulation of this UCP-1 and increases in oxidative 
phosphorylation genes indicate that women express more metabolically active fat 
mass in comparison to men. Understanding that women have more metabolically 
active fat may help to explain the differing symptoms seen in MetS between men 
and women.
MetS and obesity can induce changes in gene expression. PPAR γ is one of 
the hormone receptors responsible for regulating adipocyte differentiation and 
lipolysis. Genetic SNP predispositions within this receptor, which are found 
in women, have been linked to increased susceptibility for obesity and insulin 
resistance [46] Estrogen can also activate a variety of metabolism genes, which 
play a role in the increased fat metabolism in humans and rodents [44, 47]. 
Women in the postmenopausal period, when estrogen levels have decreased, 
have a higher incidence in central adiposity and a higher risk for developing MetS 
[48]. Contrastingly, throughout life men have larger muscle mass and less free fat 
in organs that are highly metabolically active like the kidneys, liver, and brain. 
Males are more likely than women to experience an increase in incidence of 
diabetes due to decreases in insulin sensitivity [46]. Men also have lower expres-
sion of oxidative phosphorylation genes and brown adipose tissue, as indicated 
by UCP1, compared to women [49]. Taken together, these data support the idea 
that men and women present with different symptoms of metabolic syndrome 
and, therefore, may need different treatments for MetS consistent with these 
symptoms.
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5.2 Cardiovascular disease
According to the American Heart Association, CVD is a term that encompasses 
many conditions including heart disease, heart valve issues, heart failure, and 
stroke. CVD is the leading cause of death for a variety of US ethnic populations 
[50]. Risk factors include metabolic syndrome, high blood lipid and glucose levels, 
high blood pressure, central/abdominal adiposity, low HDL, and high LDL choles-
terol [46]. Further, there are differences in the prevalence of CVD among race, sex, 
and hormone levels [50]. Classically, men have higher levels of CVD than women, 
until women reach the postmenopausal period, the sixth decade of life, where 
women have similar or higher incidence of CVD than males of the same age [50].
Obesity, specifically abdominal adiposity, is a main risk factor for CVD. The 
Framingham Heart Study, a long-term observational study, determined that obesity 
increases cardiovascular disorders by 64% for women and 46% for men [51]. 
Further, Garcia et al. have shown that obesity more greatly impacts women’s risk 
and incidence of CVD than men [52]. Therefore, reducing and preventing obesity 
could be a critical method for mitigating cardiovascular-related disorders in both 
men and women.
Fat accumulation of the neck has been found to be a strong predictor of CVD 
[53]. Fat accumulation is usually estimated via the measuring the neck circumfer-
ence. In contrast to the well-defined and studied compartments and sex differences 
in accumulation with the abdominal fat deposition, less is known about these 
factors in the neck. In one retrospective study, overweight and obese women have 
more subcutaneous neck fat compared to men even after age and BMI matching. 
In the same study, subcutaneous neck fat was associated with higher incidence of 
metabolic risk than intermuscular fat deposits in both sexes [54]. This suggests 
that similar to abdominal fat, women have more subcutaneous fat and men more 
intermuscular fat in the neck.
Obesity creates an inflammatory state of the body that affects heart health. 
However, the overall effects may differ among the sexes based on sex hormone 
activity. Men have a higher overall incidence of death due to CVD [50]. The X 
chromosome in men upregulates the expression of genes responsible for functions 
of cell death mechanisms and cellular trafficking/migration, while the Y chromo-
some is responsible for genes involved in innate immunity activation. Activating 
the innate immune system, specifically the immune cell, the macrophages, induces 
inflammation and increases the risk for developing atherosclerosis [46]. Therefore, 
by inheriting a Y chromosome, men increase their genetic risk for developing 
CVD. Data suggests that testosterone does not confer any protection against obesity, 
inflammation, and CVD [46].
Levels of the sex hormone estrogen do not appear to affect men as severely as 
women [46]. It is hypothesized that the gender difference of varying estrogen levels 
only becomes evident in postmenopausal women who have lower levels of this sex 
hormone. Treatment and prevention methods using statins for CVD have been 
targeted more at men than women, as deemed appropriate by the American Heart 
Association. However, guidelines have recently been tailored to be more gender-
inclusive based on cardiovascular risk factor assessments [52]. Sex differences 
attributed to genetic factors and lifestyle habits lead women to be more susceptible 
to CVD with elevated risk if preventative methods are not taken. Sex differences in 
CVD arise as the result of a combination of effects from various genetic and envi-
ronmental factors.
Another important sex difference in CVD is the effect of the sex hormone 
estrogen. Circulating levels of estrogen fluctuate during a woman’s life span and can 
regulate inflammation. Inflammation increases cardiovascular risk, as indicated 
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by increased levels of C-reactive protein [52]. CRP is both an inflammatory protein 
and an important biomarker of cardiovascular damage. It is hypothesized that 
the higher levels of systemic estrogen, associated with pre-menopausal women, 
have been shown to have a cardioprotective effect and reduce inflammation. The 
Women’s Health Initiative designed a study to determine the possible use of hor-
mone therapy as a preventative measure against CVD in postmenopausal women. 
The initial trials were ended early due by the Data Safety Monitoring Board (DSMB) 
due to the increased incidence of stroke and breast cancer in the estrogen + pro-
gesterone arm of the trial [55]. Further analysis of this randomized control study 
ultimately provided evidence for a concept known as the “timing hypothesis.” This 
hypothesis states that hormone replacement therapy near the onset of menopause, 
within 5 years, may lower the risk for CVD, while MHT treatment in women greater 
than 5 years from menopause is harmful [56]. The timing hypothesis has had an 
important impact in clinical settings [30].
Traditional CVD risk factors that are increased for women include lack of physi-
cal activity, smoking, diabetes, obesity, dyslipidemia, and hypertension. Many of 
these risk factors are highly prevalent in the United States, meaning comorbidities 
are associated with CVD. For example, every two in three adults are overweight or 
obese, highly increasing their risk to develop CVD as well as other conditions [52]. 
These risk factors are preventable and reducible by means of lifestyle changes such 
as eating a healthy diet and maintaining exercise. Some nontraditional risk factors 
for women CVD include the following: depression, autoimmune diseases, treatment 
for breast cancer, hypertensive pregnancy disorders, gestational diabetes, delivering 
a preterm child, and ischemic heart disease [52]. It is hypothesized that women with 
ischemic heart disease have higher mortality rates and worse CVD outcomes than 
men due to insufficient detection and treatment options.
One method to improve adipose deposition detection is through imaging, as 
advancements in technology have allowed for detailed assessment of subcutaneous 
and visceral fat compartments. Computed topography (CT) and magnetic reso-
nance imaging (MRI) are considered the gold standard for detailed assessment of 
body composition. However, these tests are expensive, not readily available, and, in 
the case of CT, associated with a significant dose of radiation. Dual-energy X-ray 
absorptiometry (DXA) is a technique used for osteoporosis screening and more 
readily available and less expensive and has relatively minimal radiation exposure. 
Therefore, it is more often used as it is able to assess body composition, such as 
fat and lean mass, and can quantify VAT and SAT accurately in obese patients 
[57, 58]. Fox et al. examined over 3000 subjects from the Framingham Heart 
Cohort who underwent CT of the abdomen [59]. They demonstrated a significant 
association between abdominal SAT and VAT in men and women and increased 
risk of hypertension, diabetes mellitus type 2, and metabolic syndrome. There 
was a stronger correlation with VAT and most of the cardiovascular risk factors. 
Interestingly, there were significant sex interactions with increasing volumes of SAT 
and VAT. Increasing volumes of SAT and VAT were more strongly and consistently 
associated with higher cardiovascular risks in women than in men [59]. These find-
ings suggest that women who accumulate more VAT have a higher cardiovascular 
risk than men with more VAT.
5.3 Type II diabetes mellitus
Type II diabetes mellitus (TIIDM) is also known as non-insulin-dependent or 
insulin-resistant diabetes and is characterized by high blood glucose, polyuria, 
and polydipsia. The most common risk factors attributed to TIIDM are poor diet 
and lack of exercise but have also been linked to obesity. TIIDM was traditionally 
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been considered a disease of adulthood, but this is rapidly changing since there is 
an increased incidence of TIIDM in children and adolescents [60]. The common 
comorbidities of TIIDM include metabolic syndrome, increased adiposity, and 
inflammatory conditions [37].
Males and females exhibit sex-specific differences in total muscle mass and 
in distribution of muscle that becomes apparent in puberty. Males typically have 
greater total muscle mass and greater in the upper body compared to the lower body 
[61]. Janssen et al. performed whole body MRI in men and women 18–88 years 
of age, and the results of their study suggested that men had significantly higher 
skeletal muscle mass than women relative to total body mass (38% vs. 31%) and that 
the sex differences were greater in the upper body (40%) than lower body (33%) 
[62]. It further showed that with aging, there is an age-associated loss of muscle 
mass, with the greatest loss in the lower body [62].
Skeletal muscle plays an important role in determining glucose homeostasis as 
the muscle mass is responsible for the majority of basal and insulin-stimulated glu-
cose uptake. In addition, impaired insulin activity at the level of the skeletal muscle 
is a central component to the clinical findings associated with TIIDM. The reported 
sex differences in muscle mass emphasize the differences of maintaining muscle 
during aging and could represent an important target in women who are at greater 
risk for sarcopenic obesity given their higher fat and lower muscle mass [63].
Studies have shown that exercise and fasting both present conditions that result 
in lower insulin levels with greater instances of insulin receptor binding. However, 
obese conditions result in greater levels of insulin with low insulin binding. A 
study conducted by Hotamisligil et al. suggests that TNF-a secretion by adipocytes 
decreases insulin-mediated glucose uptake by lowering the usage of glucose by 
fat and muscle tissues [64]. Insulin aids in glucose uptake in conjunction with the 
GLUT4 receptor. However, with the inability of insulin to properly interact with its 
receptor, GLUT4 is unable to take up glucose, and it continues to circulate through-
out the blood [65]. The increased blood glucose and the increased inflammatory 
cytokines produced by the adipose tissue exacerbate TIIDM pathology.
If the levels of adipokines and free fatty acids rise, their presence will result in 
the recruitment of inflammatory cell types such as macrophages. When the inflam-
matory cells are recruited to the adipose tissue, they become activated and release 
additional cytokines such as TNF-alpha and IL-6 to recruit even more inflammatory 
cells. This results in a positive feedback loop that results in a chronic state of inflam-
mation. Inflammation-resolving proteins such as annexin A1 are typically increased 
in obese patients but are inactivated by dysregulated cleavage [66]. Cleavage of 
annexin A1 deactivates the inflammation-resolving properties of the protein, lead-
ing the patient to maintain a chronic state of inflammation [66].
Various estrogen replacement therapy studies have shown that estrogen provides 
anti-inflammatory and antioxidant effects in women [67]. A meta-analysis of 
these studies investigated the effects of replacement therapy on women based on 
the age they start therapy and noted that when women began therapy within 10 
years of entering the postmenopausal phase of life, estrogen provided protective 
anti-inflammatory and antioxidant effects [12]. When women present with TIIDM, 
the benefits of estrogen are also lost regardless of age of onset, and they begin to 
present with the same diseases that are typically more prevalent in postmenopausal 
women [68].
The loss of estrogen protection after TIIDM diagnosis causes the female body 
to be attacked more aggressively compared to men of the same age. Men diagnosed 
with TIIDM have significantly lower levels of testosterone compared to healthy 
men, while women have significantly higher levels of testosterone [69]. These data 
suggest that the sex hormones can regulate TIIDM severity in both men and women.
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5.3.1 Chronic kidney disease in TIIDM
TIIDM diagnosis increases the risk of kidney stones and hypertension, both of 
which are precursors for CKD [70]. CKD is not usually diagnosed until the patient 
goes to the doctor for a physical, and they are diagnosed with high blood pressure, 
or protein is found in the urine. The Centers for Disease Control has estimated that 
as of 2015, 14% of the US population lives with CKD; of those that live with CKD, 
approximately 22% also have TIIDM.
Recent studies have shown parallels between the obesity epidemic and the onset 
of CKD. Obese patients with CKD are often seen with glomerular scarring, also 
known as glomerulosclerosis. This is now being termed obesity-related glomeru-
lopathy due to its prevalence in obese patients [71]. Development of this condition 
has been related to lipid accumulation in the kidneys which may be a response to 
hyperfiltration if the patient also has TIIDM [71]. Under normal conditions glucose 
is not filtered through the glomerulus. However, if a patient has unregulated TIIDM, 
glucose is constantly being filtered out through the glomerulus, which becomes more 
permeable when blood glucose levels are high. When the glomerulus is constantly 
filtering glucose, the glomerular net becomes weak and more permeable to other 
large molecules such as proteins. This eventually leads to total dysregulation of the 
glomerulus and, ultimately, CKD [72]. Diabetic kidney disease is the leading cause of 
CKD worldwide and affects over 40% of patients diagnosed with TIIDM [73].
The overall increase in adiposity in obesity in patients with TIIDM is also cor-
related with an increase in kidney stone formation. Due to the increased levels of 
circulating adipokines released by the engorged adipocytes, these patients have an 
overall inflamed profile that results in higher levels of oxidative stress that can lead 
to the development of nephrolithiasis or kidney stones. Chronic kidney stone for-
mation can also affect glomerular filtration rate and lead to CKD [70]. This increase 
in oxidative stress further upregulates inflammation in a positive feedback loop that 
can eventually lead to CKD and more serious pathology.
Advanced diabetes-related kidney disease is more prevalent in women than in 
men. However, men have a greater risk of onset. This difference may stem from 
how diabetes negates the protective qualities of estrogen. The effects of TIIDM 
on testosterone are unknown but do not appear to lead to progression of diabetes-
related kidney disease. Women with TIIDM appear to have diabetic kidney disease 
more severely than men [74–76]. Obesity-related CKD that does not coincide with 
metabolic abnormalities is more prominent in men than women [77]. Estrogen may 
prevent kidney dysregulation in women, but these protective effects are negated in 
women with metabolic abnormalities.
5.4 Cancer
Approximately 14% of cancer deaths in men and 20% of cancer deaths in women 
can be attributed to obesity [78]. This can be related to the activation of signal-
ing pathways in adipocytes which lead to secretion of low levels of inflammatory 
cytokines by the adipocytes, thereby leading to low-grade inflammatory responses 
throughout the body in locations where fat is most present [78]. Similarly, obesity 
increases endoplasmic reticulum stress resulting in oxidative stress, the unfolded 
protein response, and the upregulation of additional inflammatory cytokines [78]. 
These different inflammatory mechanisms can all contribute to the formation and 
progression of cancer, making obesity a deadly player in the onset of certain cancers.
The incidence of certain sex-linked cancers, such as breast cancer, may be 
upregulated in obese patients. In women specifically, the dysregulation of hor-
mones that is linked with obesity can exacerbate the onset of breast cancer [79]. 
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Non-sex-linked cancers, such as liver cancer, may also have an increased risk in 
relation to obesity [78]. The obesity-related development of nonalcoholic fatty 
liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and NASH-related 
cirrhosis are also associated with an increased risk of hepatocellular carcinoma 
[78]. By affecting both sex-linked and non-sex-linked cancers, obesity’s wide range 
of potential effects on tumor initiation and progression could contribute to an 
increased prevalence of cancer in obese patients.
A meta-analysis of cohort studies done by Larsson and Wolk found that obese 
individuals had an 89% increased risk of liver cancer [80]. However, the relative 
risk for liver cancer was significantly higher in men than in women, indicating that 
there may be hormone-dependent mechanisms at play [80]. Secretion of proinflam-
matory cytokines including IL-6, IL-8, IL-10, and IL-17 by hypertrophic adipocytes 
triggers an inflammatory cascade in the liver [81]. Damage induced by these inflam-
matory mediators can cause carcinogenesis. Further, the AMPK-TORC1 pathway 
that regulates autophagy is decreased by obesity and hypernutrition [81]. The 
decrease in the autophagy pathway causes a decrease in the clearance of damaged 
cellular organelles which can further induce inflammation and carcinogenesis.
Obesity may be a driving force in sex-related cancers such as prostate cancer 
and breast cancers in men and women. In women, obesity is related to a higher 
incidence of pre-menopausal triple-negative breast cancers, while ER-positive 
breast cancers had a higher incidence among postmenopausal women [82]. This 
is suggested in that breast cancer progression in pre-menopausal obese women is 
not affected by high amounts of systemic estrogen. However, in postmenopausal 
women, with normally low circulating estrogen levels, the incidence in ER-positive 
breast cancer increases. Additionally, the obesity associated risk with triple-neg-
ative breast cancer in postmenopausal women is inversely associated with obesity 
[82]. Among men, obesity and BMI are strong risk factors for male breast cancer 
[83]. Studies have shown that male breast cancer tumors show an increase in the 
estrogen and progesterone receptors [84]. The hormone aromatase, produced by the 
adipose tissue, plays a role in increasing estrogen levels by converting testosterone 
into estrogen and can therefore exacerbate breast cancer in obese men.
In summary, studies have indicated that there are sex-related differences in 
relation to obesity and the onset of cancer, specifically in response to breast cancers. 
Low-grade inflammation as a result of obesity seems to be an underlying cause of 
the disruption of important protective pathways, contributing to the initiation and/
or progression of cancer.
5.5 Neurodegeneration
Neurodegeneration involves the gradual breakdown of the nervous system and 
causes anxiety, dysphoria, apathy, disinhibition, and euphoria [85]. Alzheimer’s 
disease, (AD) the most common neurodegenerative disease and the sixth leading 
cause of death in the United States, is the cause of death in one in three seniors 
living in the United States [86]. It is estimated that 5.7 million Americans are 
affected by Alzheimer’s, two-thirds of which are women [86]. Currently AD is the 
only unpreventable, untreatable disease of the top 10 leading causes of death in the 
United States [86]. While the cause of Alzheimer’s may be unknown, research has 
shown strong links between neurodegeneration and obesity.
AD and other dementias occur more commonly in women than in men world-
wide suggesting that there may be some sex-specific hormonal influences to the 
progression of the disease [87]. Although the specific hormonal influences are not 
known, men may have a certain ability to protect themselves against the severity of 
neurodegeneration, or women may simply lose their ability to do so. As awareness 
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increases, TIIDM is becoming recognized as a contributor to the risk of developing 
AD [88]. The widespread association between TIIDM and neurodegenerative dis-
eases may eventually wind up providing a link between the two. With the expected 
population diagnosed with diabetes reaching 573 million within 12 years by the 
World Health Organization, research into the implications of diabetes and other 
overnutrition illness is becoming essential [89].
Neurodegeneration related to over nutrition has been shown to have profound 
implications on the functionality of the central nervous system and cerebral func-
tions in particular. Recently, the IKK-beta/NF-kappaB pathway has been shown 
to be triggered by overnutrition, leading to inflammation of the hypothalamus 
and other CNS peripheral tissues [90]. This is critical because the hypothalamus is 
responsible for regulating functions such as energy balance as well as controlling 
some metabolic activities related to the sympathetic and parasympathetic nervous 
systems [90]. This inflammation due to overnutrition has been deemed “metabolic 
inflammation” [90].
A diet that is high in fat may contribute to the progression of neurodegeneration 
through increased fatty acid uptake. Saturated fatty acids cause activation of the 
immune system through Toll-like receptor 4 (TLR4), leading to the production of 
cytokines by astrocytes [91]. This thereby induces an inflammatory response that 
could lead to damage of the hypothalamus. Additionally, loss of normal function 
of the TLR4 increases and encourages diet-induced obesity [91]. This positive 
feedback loop would encourage inflammation while also sustaining the nutrient- 
and fat-rich environment in which it was produced. Microglia, macrophages in the 
brain, produce inflammasomes in diseased states such as obesity and TIIDM [91]. 
Therefore, any inflammation already pre-existing in the body due to obesity would 
only encourage self-damaging signaling cascades. These processes hijack the body’s 
natural defense mechanisms to further the progression of neurodegeneration.
Advanced glycation end products, or AGEs, are markers of carbonyl stress due to 
oxidative stress, and their formation is irreversible and leads to protein deposits and 
amyloidosis [92]. Unnatural amyloid deposits in critical areas of the central nervous 
system can result in irregularities of normal functioning, and AGE formation seems 
to occur early in the stages of plaque formation in connection with AD [92]. AGE 
leads to a release of free radicals that are associated with the oxidation of sugars which 
eventually can lead to site-specific attacks of proteins and lipid peroxidation [92]. 
Additionally, when AGEs induce the expression of AGE cell surface receptors (RAGE), 
superoxide radicals and hydrogen peroxide are released, further contributing to cyto-
toxic effects on cells and inflammation [92]. The combination of these effects continues 
to incite an inflammatory response and furthers the progression of the neurodegenera-
tive diseases and other neurological damages. These findings support the claim that 
hyperglycemia-derived AGEs constitute a crucial link between diabetes and AD [91].
Diabetes mellitus may serve as a very relevant risk factor for AD. This link may 
be due to the existence of insulin resistance in both patients affected by TIIDM and 
in neural cells [93]. Insulin receptors activate receptor tyrosine kinases which in 
turn phosphorylate insulin receptor subtypes 1 and 2 [93]. The interaction of these 
receptors with Src domains allows for several protective processes to occur and 
promote cellular division and longevity of healthy cells [93]. Cells that are deficient 
in this receptor, or that cannot express sufficient amounts, are subsequently at risk 
for diminished functioning capabilities. Furthermore, insulin specifically binds to 
the respective receptors to initiate different functions, so the expression of both 
receptors is vital to cellular functioning [93]. In the brain, the highest levels of 
insulin are found in the hypothalamus, temporal lobe, and cerebellum [93]. A lack 
of the protecting effects of insulin may explain why the hypothalamus is classically 
inflamed in conditions of obesity.
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Obesity-associated low-grade inflammation seems to be an underlying cause in 
the progression of neurodegenerative diseases, specifically AD. While there seem 
to be sex-related differences in the relationship between neurodegeneration and 
obesity, more research is needed to identify what the exact cause is. Nevertheless, 
the correlation between neurodegeneration, TIIDM, and obesity is apparent, and 
further research is needed to elucidate this mechanism.
5.6 Infertility
Infertility is defined as the inability of a couple to conceive after 12 months or 
more of regular, unprotected sex [94]. There can be many causes of infertility, but an 
emerging comorbidity and risk factor is obesity. Obesity can affect reproduction and 
development by altering sex hormones, sex cells, and different genes within the sex 
cells. These alterations can be found in both men and women; however, the effects 
differ slightly. Both sexes exhibit an increase of the androgen sex hormone [95, 96]. 
Obese men and women are also shown to produce less sex cells overall [97]. A 2015 
epidemiological study found that over 100 genes that were related to infertility were 
also related to obesity [95, 96]. Furthermore, genes that support sex cell matura-
tion and function have been shown to be altered with an increase in adiposity [98]. 
Maintaining a healthy body weight can help normalize these factors of reproduction, 
while obesity can cause reproductive alterations that can result in infertility.
5.6.1 Males
Infertility in males is linked to decreased viable sperm count, sperm motility, 
or supporting sex hormones. When compared to men with a normal body mass 
index (BMI) of 20–25 kg/m2, obese men with a BMI greater than 25 kg/m2 showed a 
decrease in concentration of the number of sperm per milliliter of ejaculatory fluid, 
a decrease in total sperm count in millions, and a decrease in healthy sperm cells 
[97]. Successful conception rates have been directly related to sperm counts; greater 
sperm counts correlate to an increased chance of conception, and in addition to 
sperm count, obesity-induced epigenetic modifications play a role in sperm-egg 
interaction [97]. Increased obesity-induced DNA methylation and decreased DNA 
acetylation affect sperm cell gene expression [99]. This change can inhibit a success-
ful fertilization by altering embryogenesis, and this can lead to a failed pregnancy 
or problems in embryo development.
In males, onset of obesity correlates with an increase in estrogen and a decrease 
in supporting sex hormones such as testosterone, sex hormone-binding globulin 
(SHBG), and inhibin B [97]. SHBG is mainly produced in the liver and primar-
ily functions by binding to and transporting sex steroids throughout the blood. 
Decreased SHBG protein levels have been linked to metabolic and endocrine 
disorders and obesity [100]. Obesity has been correlated with low secretion levels 
of luteinizing hormone (LH) from the pituitary gland, which induces testosterone 
release from the Leydig cells. In a healthy male, after testosterone secretion, a 
majority of the steroid would bind to SHBG and then travel to various androgen 
receptors throughout the male body, with small levels being converted to estrogen 
via aromatase. However, obese patients tend to have a greater aromatase activity 
and therefore have higher levels of estrogen than nonobese men [99]. An increase in 
metabolism of free testosterone to estrogen can lead to decreased testicular sensitiv-
ity to LH, further leading to high estrogen and low testosterone levels [99]. This cre-
ates a negative feedback loop, ultimately leading to a decrease in sperm production.
Inhibin B is a glycoprotein produced by Sertoli cells that aids in regulating 
follicle-stimulating hormone (FSH) in a negative feedback manner [101]. When 
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spermatogenesis appears to be elevated based on activity of the hypothalamic-
pituitary-gonadal hormone (HPG), this indicates a high sperm count due to FSH 
secretions. Inhibin B will regulate FSH levels based on HPG status which modu-
lates sperm concentration. An inhibin B study found that a negative correlation 
between sperm count and inhibin B was revealed [101]. Inhibin B activity is high 
when sperm count is concentrated; infertile men often have very low levels of 
inhibin B; this relationship indicates further exacerbation of infertility and low 
sperm count. Decreased gonadal function in obese men has been characterized 
by lower levels of inhibin B even though FSH levels remain similar before and 
after weight loss [102]. Therefore, while obese males have similar levels of FSH to 
nonobese males, the high aromatase activity converts much of the testosterone to 
estrogen, thereby inhibiting spermatogenesis and decreasing fertility [103].
Lastly, in healthy males, the scrotum usually is about 2–3°C lower than body 
temperature, which is essential for sperm storage, health, and motility [104]. 
Obesity can also result in increased scrotum temperatures which can lead to infertil-
ity [104]. The changes associated with obesity-induced infertility can be circum-
vented by weight loss [104]. Staying healthy and maintaining a moderate BMI can 
help regulate hormone and sex cell secretions and promote fertility.
5.6.2 Females
Obesity in females can lead to infertility by decreasing oocyte quality, altering 
ovulation, and affecting developmental factors. The mitochondria and mitochon-
drial oxidative phosphorylation are essential to oocyte maturation, fertilization, 
and implantation [105]. It has been shown that mice lacking the mitochondrial 
replication protein, TFAM, are embryonic lethal and reduced levels of TFAM cause 
decreased fertility [106]. The effects of high-fat diet (HFD) on obesity are summa-
rized in Grindler et al. but briefly show that HFD-induced obesity alters mitochon-
drial function and mitochondrial membrane potential, increases reactive oxygen 
species, and decreases mitochondrial DNA copy number in oocytes which indicates 
damaged and unhealthy oocytes [105]. Regular diets with less fat would minimize 
mitochondrial dysfunction and oxidative damage to oocytes and keep them viable.
Menstrual abnormalities contributing to infertility like anovulation are seen 
in obese women [107]. SAT plays a role in regulating anovulation, whereas VAT 
plays more of a role in proinflammatory secretions [108]. Regulating fat intake 
can improve chances of conception by regulating menstrual cycles and oocyte 
development. Further, the proinflammatory secretions from VAT create a positive 
feedback loop causing more inflammation and more ovulation complications. The 
changes in ovulation and the increased levels of inflammatory cytokines exacer-
bate infertility in females.
Regulation of the follicular environment is necessary for oocyte development, 
and obesity changes the follicular environment and consequently the oocyte gene 
expression which contribute to infertility [109]. Leptin is typically elevated in obese 
patients and can cause negative changes to the follicular environment. Interestingly, 
women with higher BMI have higher levels of lactate, triglycerides, and CRP and 
decreased levels of SHGB in their follicular fluid, compared to normal-weight 
women, which can be linked to decreased oocyte viability and an inhospitable 
environment for oocyte development [109]. In addition, the same decrease in 
SHBG seen in obese men was seen in obese women [109]. This decrease in SHBG 
expression would lead to decreased transport of estrogen and thereby decreased 
oocyte development. This suggests that secretions from adipose tissues could be 
contributing to decreased oocyte function. Further, when oocytes were extracted 
from women of BMIs considered normal, overweight, and obese, fewer oocytes 
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were obtained from the women in the obese category with a BMI of greater than 
30 kg/m2 [109]. Taken together this data indicates that obesity impairs oocyte 
development.
The increase in C-reactive protein suggests that systemic inflammation can 
also affect fertility and oocyte development [109]. High amounts of inflammatory 
secretions such as C-reactive protein seen in obese women contribute to decreased 
fertility. Obesity-induced inflammation presents damaging effects to oocytes and 
contributes to infertility. Obesity decreases chances of healthy oocyte fertilization 
and implantation. Couples will have a better chance at conception and successful 
pregnancy if a healthy weight is maintained.
5.7 Stress
Obesity and stress cause a vicious positive feedback loop to cause more obesity 
and stress. Outside stressors activate the sympathetic nervous system and the 
hypothalamic-pituitary-adrenal (HPA) axis. When these systems are dysregulated 
by continuous stress, the hyperactivity causes health issues, such as obesity [110]. 
Under normal conditions, the HPA axis is needed to maintain energy and metabolic 
homeostasis through modulating hormones such as insulin and leptin [111]. When 
activated, the sympathetic nervous system will cause secretion of epinephrine and 
norepinephrine from the adrenal gland, and the HPA axis will release cortisol. 
Negative feedback mechanisms inhibit the HPA axis from continuously secreting 
cortisol and maintaining alterations in metabolism [112]. Homeostatic fluctuation 
of the HPA axis controls metabolism; however, stress and inflammation alter this 
feedback loop and contribute to metabolic dysfunction.
Obesity-induced inflammation has also been correlated with an increase in 
the HPA axis function. Cortisol can increase leptin levels and inhibit leptin from 
suppressing appetite, or cortisol can induce neuropeptide Y release, which stimu-
lates fat growth [110]. Therefore, cortisol can increase fat deposition. The origin 
of cortisol, from stress or normal homeostatic activation, and the obesity status 
play a role in fat deposition. For example, stress-induced increases in cortisol levels 
cause women to gain more weight compared to non-stressed women with the 
same cortisol levels. Further, elevated cortisol levels in overweight women cause 
increased weight gain at a faster pace than women with average weight and similar 
elevated cortisol levels [110]. The correlation between cortisol and weight gain in 
men appears to be related more to weight gain than to increases in cortisol levels, 
and the increased cortisol production seen in men could be further stimulated by 
the inflammatory cytokines secreted in fat tissues [110]. Together, this data suggests 
gender differences in cortisol-induced adiposity.
Stress can affect choice of food intake differently in males and females by 
modulating appetite. While most individuals were seen to eat less in high stress, 
individuals were seen to eat more in continuous low or moderate stress levels [113]. 
This suggests that prolonged moderate stress could contribute more to obesity 
than high stress in a shorter time period. Not only does stress increase appetite for 
some people, but it also affects food choice. Individuals under stress were seen to 
increase the intake of higher-calorie “comfort foods” in replacement of vegetables 
[111]. These findings support the role of stress-induced weight gain in chronically 
stressed people.
Ideas of self-image, ideal weight, or body shape also lead to increased stress. 
The ideas of normal or desired body image are found everywhere and are often 
unrealistic and idealized. The role of weight-based stigmas and how they differ 
in males and females offer inconclusive results [114]. In a recent study by Sattler 
et al., weight-based stigmas in obese population caused weight gain and a decreased 
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desire to exercise in females more than males [114]. Females with weight-associated 
stigmas had less motivation to participate in physical activities, while males had 
more motivation to exercise [114]. These stigmas can cause increases in stress levels 
and cortisol release and may actually have a negative impact on exercise and weight 
loss in obese patients. The idea that this weight stigma differentially affects males 
and females is important to understand, in order to effectively motivate overweight 
and obese males and females to exercise and to lose weight. This data suggests that 
the stress of ideal body image can also negatively affect stress-induced adiposity.
Stress and obesity combined contribute to fat growth, changes in appetite, and 
additional stress. The negative self-image, depression, or anxiety that obese people 
have provides the stress for prolonged HPA axis activation and increased adiposity.
6. Conclusion
Obesity plagues approximately 70% of US adults. Obese adipose tissue is 
responsible for releasing proinflammatory cytokines throughout the body as well 
as dysregulating glucose-regulating hormones. Chronic obese adiposity puts the 
body in a state of chronic inflammation which leads to numerous diseases includ-
ing CVD, TIIDM, MetS, cancer, neurodegeneration, and infertility (Figure 2). 
Sex differences play a role in regulating the prevalence of disease, causing 
sexual dimorphism in diseases and disease pathogenesis in men than women. 
The role of the sex hormones, estrogen, and testosterone should be further 
explored in order to most effectively treat obese patients and their numerous 
pathophysiologies.
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Figure 2. 
The relationship between obesity, inflammation, and disease. Obesity, inflammation, and chronic diseases cause 
a vicious cycle, each exacerbating the other. Inflammatory cytokines and adipokines are produced systemically 
and by adipocytes, respectively, and play a role in exacerbating disease states. Prevalence of disease caused by 
inflammation and obesity varies between men and women, and sex differences may be due to the proposed 
protective nature of the primary female sex hormone, estrogen.
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